Furthermore, the study suggests potential therapeutic implications of ANGPTL3 inhibition for both hypothyroidism and hyperthyroidism, alongside the observed risk increase in hyperthyroidism with LPL activation. The gene discussed is ANGPTL3; the disease is hypothyroidism.